JP2021040555A - 核酸試料の品質評価方法 - Google Patents
核酸試料の品質評価方法 Download PDFInfo
- Publication number
- JP2021040555A JP2021040555A JP2019166054A JP2019166054A JP2021040555A JP 2021040555 A JP2021040555 A JP 2021040555A JP 2019166054 A JP2019166054 A JP 2019166054A JP 2019166054 A JP2019166054 A JP 2019166054A JP 2021040555 A JP2021040555 A JP 2021040555A
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- sample
- oligonucleotide primer
- seq
- set forth
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108020004707 nucleic acids Proteins 0.000 title claims abstract description 150
- 102000039446 nucleic acids Human genes 0.000 title claims abstract description 150
- 150000007523 nucleic acids Chemical class 0.000 title claims abstract description 150
- 238000000034 method Methods 0.000 title claims abstract description 36
- 238000003199 nucleic acid amplification method Methods 0.000 claims abstract description 57
- 108091034117 Oligonucleotide Proteins 0.000 claims abstract description 55
- 230000003321 amplification Effects 0.000 claims abstract description 51
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 25
- 210000005260 human cell Anatomy 0.000 claims description 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 4
- 238000012300 Sequence Analysis Methods 0.000 abstract description 4
- 239000002773 nucleotide Substances 0.000 abstract description 3
- 125000003729 nucleotide group Chemical group 0.000 abstract description 3
- 239000013615 primer Substances 0.000 description 71
- 239000000523 sample Substances 0.000 description 69
- 210000004027 cell Anatomy 0.000 description 57
- 238000004458 analytical method Methods 0.000 description 24
- 239000000047 product Substances 0.000 description 19
- 206010028980 Neoplasm Diseases 0.000 description 15
- 108090000623 proteins and genes Proteins 0.000 description 15
- 238000011282 treatment Methods 0.000 description 15
- 201000011510 cancer Diseases 0.000 description 13
- 238000013441 quality evaluation Methods 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 9
- 210000005266 circulating tumour cell Anatomy 0.000 description 9
- 239000000758 substrate Substances 0.000 description 8
- 238000001514 detection method Methods 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 230000000295 complement effect Effects 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 206010064571 Gene mutation Diseases 0.000 description 5
- 239000007850 fluorescent dye Substances 0.000 description 5
- 230000014759 maintenance of location Effects 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 238000013412 genome amplification Methods 0.000 description 4
- 239000012212 insulator Substances 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 241000282412 Homo Species 0.000 description 3
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 3
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 125000006850 spacer group Chemical group 0.000 description 3
- 239000012128 staining reagent Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 239000000811 xylitol Substances 0.000 description 3
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 3
- 229960002675 xylitol Drugs 0.000 description 3
- 235000010447 xylitol Nutrition 0.000 description 3
- 239000003155 DNA primer Substances 0.000 description 2
- 108060006698 EGF receptor Proteins 0.000 description 2
- 102000001301 EGF receptor Human genes 0.000 description 2
- 101150068332 KIT gene Proteins 0.000 description 2
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 2
- 101150019443 SMAD4 gene Proteins 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 239000002853 nucleic acid probe Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 101150090724 3 gene Proteins 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 101150039808 Egfr gene Proteins 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 238000007397 LAMP assay Methods 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 101150080074 TP53 gene Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 230000002153 concerted effect Effects 0.000 description 1
- 239000004020 conductor Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 108700021358 erbB-1 Genes Proteins 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000001215 fluorescent labelling Methods 0.000 description 1
- 238000012215 gene cloning Methods 0.000 description 1
- 238000012252 genetic analysis Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000000138 intercalating agent Substances 0.000 description 1
- 238000002032 lab-on-a-chip Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 108700025694 p53 Genes Proteins 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 229920000729 poly(L-lysine) polymer Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000012521 purified sample Substances 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
Abstract
Description
反応に供し、核酸増幅産物の有無またはその量に基づき評価する方法が知られている(特許文献1、非特許文献1から2)。しかしながら核酸増幅反応においては、標的核酸とハイブリダイズ可能なオリゴヌクレオチドの組み合わせ、すなわちフォワードプライマー(第一のプライマー)とリバースプライマー(第二のプライマー)との組み合わせ(以下、プライマーセットとも表記)を最適化する必要がある。さらに核酸試料の品質評価にあたって、増幅対象とする標的核酸上の領域(標的領域)は複数あると好ましい。複数の標的領域を用いた品質評価を行なう際、当該標的領域とハイブリダイズ可能なプライマーセットを標的領域毎に用意し、当該用意した複数のプライマーセットを含む核酸増幅試薬で複数の標的領域を同時に増幅し得るマルチプレックス核酸増幅を行なうと好ましい。しかしながらマルチプレックス核酸増幅ではプライマー同士の干渉などにより非特異的な増幅や増幅効率の低下が発生しやすく、プライマーセットの最適化が課題である。
試料中に含まれる核酸を、当該核酸とハイブリダイズ可能なオリゴヌクレオチドプライマーセットを含む核酸増幅試薬と反応させる工程と、
前記反応工程で得られた核酸増幅産物量を評価する工程とを含む、
試料中に含まれる核酸の品質を評価する方法であって、
前記核酸がヒト細胞由来の核酸であり、前記オリゴヌクレオチドプライマーセットが、少なくとも下記(a)から(d)に示す、いずれか一つである、前記方法である。
(a)配列番号1に記載の配列を少なくとも含むオリゴヌクレオチドプライマーと、配列番号2に記載の配列を少なくとも含むオリゴヌクレオチドプライマーとのセット
(b)配列番号3に記載の配列を少なくとも含むオリゴヌクレオチドプライマーと、配列番号4に記載の配列を少なくとも含むオリゴヌクレオチドプライマーとのセット
(c)配列番号5に記載の配列を少なくとも含むオリゴヌクレオチドプライマーと、配列番号6に記載の配列を少なくとも含むオリゴヌクレオチドプライマーとのセット
(d)配列番号7に記載の配列を少なくとも含むオリゴヌクレオチドプライマーと、配列番号8に記載の配列を少なくとも含むオリゴヌクレオチドプライマーとのセット。
(A)電気泳動や液体クロマトグラフィーを用いた方法、
(B)検出可能な標識で標識された核酸プローブによるハイブリダイゼーション法、
(C)当該増幅産物の塩基配列の一部とハイブリダイズすることで蛍光特性が変化するように設計された蛍光色素標識プローブを用いた方法。
以下に示す方法で、ヒトがん細胞株一細胞から、核酸試料を調製した。
以下に示す方法で、実施例1で調製した核酸試料の品質評価を行なった。
(反応液組成)
HotStarTaq Master Mix(キアゲン社製) 12.5μL
RNase−free水 10μL
5μMプライマーMix溶液 1.5μL
核酸試料(実施例1) 1μL
(反応温度)
95℃で15分間:1サイクル
94℃で30秒間、55℃で30秒間、72℃で60秒間:40サイクル
72℃で10分間:1サイクル
(3)Agilent 2100 バイオアナライザおよびAgilent DNA1000キット(いずれもアジレント・テクノロジー社製)を用いてDNAの増幅を確認した。
以下に示す方法で、核酸試料の遺伝子変異解析(がん関連遺伝子のターゲットシーケンスによる変異解析)を行った。
11:遮光部材
12:絶縁体
11a・12a:貫通孔
20:スペーサー
21:導入口
22:排出口
23:貫通部
31・32:電極基板
40:導線
50:信号発生器
60:保持部
70:標的細胞(がん細胞株)
200:蛍光顕微鏡
300:誘電泳動力
400:マイクロマニピュレーター
Claims (1)
- 試料中に含まれる核酸を、当該核酸とハイブリダイズ可能なオリゴヌクレオチドプライマーセットを含む核酸増幅試薬と反応させる工程と、
前記反応工程で得られた核酸増幅産物量を評価する工程とを含む、
試料中に含まれる核酸の品質を評価する方法であって、
前記核酸がヒト細胞由来の核酸であり、前記オリゴヌクレオチドプライマーセットが、少なくとも下記(a)から(d)に示す、いずれか一つである、前記方法:
(a)配列番号1に記載の配列を少なくとも含むオリゴヌクレオチドプライマーと、配列番号2に記載の配列を少なくとも含むオリゴヌクレオチドプライマーとのセット
(b)配列番号3に記載の配列を少なくとも含むオリゴヌクレオチドプライマーと、配列番号4に記載の配列を少なくとも含むオリゴヌクレオチドプライマーとのセット
(c)配列番号5に記載の配列を少なくとも含むオリゴヌクレオチドプライマーと、配列番号6に記載の配列を少なくとも含むオリゴヌクレオチドプライマーとのセット
(d)配列番号7に記載の配列を少なくとも含むオリゴヌクレオチドプライマーと、配列番号8に記載の配列を少なくとも含むオリゴヌクレオチドプライマーとのセット。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2019166054A JP7371405B2 (ja) | 2019-09-12 | 2019-09-12 | 核酸試料の品質評価方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2019166054A JP7371405B2 (ja) | 2019-09-12 | 2019-09-12 | 核酸試料の品質評価方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2021040555A true JP2021040555A (ja) | 2021-03-18 |
JP7371405B2 JP7371405B2 (ja) | 2023-10-31 |
Family
ID=74861442
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019166054A Active JP7371405B2 (ja) | 2019-09-12 | 2019-09-12 | 核酸試料の品質評価方法 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP7371405B2 (ja) |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6009096B2 (ja) | 2012-11-26 | 2016-10-19 | ザ・ユニバーシティ・オブ・トレド | 核酸の標準化された配列決定のための方法およびその使用 |
EP3356382A4 (en) | 2015-09-25 | 2019-04-03 | Contextual Genomics Inc. | MOLECULAR QUALITY ASSURANCE PROCEDURE FOR USE IN SEQUENCING |
-
2019
- 2019-09-12 JP JP2019166054A patent/JP7371405B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
JP7371405B2 (ja) | 2023-10-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20230069046A1 (en) | Methods for increasing resolution of spatial analysis | |
US11015227B2 (en) | Methods and compositions to generate unique sequence DNA probes, labeling of DNA probes and the use of these probes | |
DK2279266T3 (en) | PROCEDURE FOR DETECTING IGF1R DIFFERENCES IN CIRCULATING TUMOR CELLS USING FISH | |
US20210382002A1 (en) | Detection methods for epitachophoresis workflow automation | |
CN114269916A (zh) | 用于样品分析的装置和方法 | |
JP2021000138A (ja) | 診断方法及び組成物 | |
Yokogami et al. | Impact of PCR-based molecular analysis in daily diagnosis for the patient with gliomas | |
Sridhar et al. | Molecular genetic testing methodologies in hematopoietic diseases: current and future methods | |
Gasch et al. | Whole genome amplification in genomic analysis of single circulating tumor cells | |
JP7371405B2 (ja) | 核酸試料の品質評価方法 | |
JP6248633B2 (ja) | 標的核酸の検出方法 | |
Mocellin et al. | Quantitative real-time PCR in cancer research | |
US20080003600A1 (en) | Isothermal screening of breast cancer related nucleic acid | |
Cao et al. | Establishment of scalable nanoliter digital LAMP technology for the quantitative detection of multiple myeloproliferative neoplasm molecular markers | |
EP2843047B1 (en) | Nucleic acid detection method | |
JP2014187934A (ja) | 標的核酸の検出方法 | |
Li et al. | Rapid detection of EGFR mutation in CTCs based on a double spiral microfluidic chip and the real-time RPA method | |
KR102353064B1 (ko) | Her2 복제수 변이 검출용 조성물 및 이를 포함하는 키트 | |
Conconi et al. | Analysis of chromosomal alterations in urothelial carcinoma | |
JP5584385B2 (ja) | ヒトパピローマウイルスの検出法及びタイピング方法 | |
Malewski et al. | RT-PCR technique and its applications. State-of the-art | |
Kashyap et al. | Local Nucleic Acid Analysis of Adherent Cells | |
CN110616266A (zh) | 用于区分肝移植供受体细胞的特异性引物对、探针、试剂盒及区分方法 | |
Long et al. | genome multiple displacement amplification |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220822 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20230630 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230704 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230829 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20230919 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20231002 |
|
R151 | Written notification of patent or utility model registration |
Ref document number: 7371405 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R151 |